

DAFTAR PUSTAKA

- Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R., *et al.* (2017, May). Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. *Clin Oncol*, 35(suppl 15): abstr 1088. DOI: 10.1200/JCO.2017.35.15_suppl.1088.
- Ademuyiwa, F. O., Groman, A., O'Connor, T., Ambrosone, C., Watroba, N., Edge, S. B. (2011). Impact of body mass index on clinical outcomes in triple-negative breast cancer. *Cancer*, 117(18): 4132-40. DOI: 10.1002/cncr.26019.
- AJCC (American Joint Committee on Cancer). (2010). *Cancer Staging Manual* (7th ed.). (S. B. Edge, C. C. Compton., Eds.) Chicago: Springer. DOI: 10.1245/s10434-010-0985-4.
- Al-Tamimi, D. M., Bernard, P. S., Shawarby, M. A., Al-Amri, A. M., Hadi, M.A. (2009). Distribution of molecular breast cancer subtypes in middle eastern-saudi arabian women: a pilot study. *Ultrastruct Pathol*, 33: 141-50. DOI: 10.1080/01913120903183135.
- Andrés, R., Pajares, I., Balmaña, J., Llort, G., Cajal, T. R., Chirivella, I., *et al.* (2014). Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC). *Clin Transl Oncol*, 16(3): 280-4. DOI: 10.1007/s12094-013-1070-9.
- Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., Caggiano, V. (2007, May). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. *Cancer*, 109(9): 1721-8. DOI: 10.1002/cncr.22618.

- Bhattacharyya, G. S., Walia, M., Nandi, M., Murli, A., Salim, S., Rajpurohit, S., *et al.* (2018). Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer. *South Asian J Cancer*, 7(2): 156-8. DOI: 10.4103/sajc.sajc_126_18.
- Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A. (2016, May). A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). *Ann Oncol*, 27(5): 812-8. DOI: 10.1093/annonc/mdw067.
- Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A., *et al.* (2015, Apr). Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. *Clin Cancer Res*, 21(7): 1688-98. DOI: 10.1158/1078-0432.CCR-14-0432.
- Busti, F., Marchi, G., Ugolini, S., Castagna, A., Girelli, D. (2018). Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. *Pharmaceuticals (Basel)*, 11(4): 94. DOI: 10.3390/ph11040094.
- Cakar, B., Muslu, U., Erdogan, A. P., Ozisik, M., Ozisik, H., Dalgic, C. T., *et al.* (2015). The Role of Body Mass Index in Triple Negative Breast Cancer. *Oncol Res Treat*, 38(10): 518-22. DOI: 10.1159/000439551.
- Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., *et al.* (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clin Cancer Res*, 13: 2329–34. DOI: 10.1158/1078-0432.CCR-06-1109.
- Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., *et al.* (2012, Jul). TBCRC 001: Randomized Phase II Study of Cetuximab in

Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer. *J Clin Oncol*, 30(21): 2615–23. DOI: 10.1200/JCO.2010.34.5579

Chen, B., Dai, D., Tang, H., Ai, X., Chen, X., Chang, X., *et al.* (2016). Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer. *PLoS ONE*, 11(11): e0165133. DOI: 10.1371/journal.pone.0165133.

Crona, D. J., Faso, A., Nishijima, T. F., McGraw, K. A., Galsky, M. D., Milowsky, M. I. (2017). A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. *Oncologist*, 22(5): 609-19. DOI: 10.1634/theoncologist.2016-0319.

Dai, D., Zhong, Y., Wang, Z., Yousafzai, N. A., Jin, H., Wang, X. (2019). The prognostic impact of age in different molecular subtypes of breast cancer: a population-based study. *PeerJ*, 7: e7252. DOI: 10.7717/peerj.7252.

Dent, R., Trudeau, M., Pritchard, K. L., Hanna, W. M., Kahn, H. K., Sawka, C. A., *et al.* (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res*, 13: 4429–34. DOI: 10.1158/1078-0432.CCR-06-3045.

DeVita, V. T. (2008). *DeVita, Hellman, and Rosenberg's Cancer: Principles Practice of Oncology* (8th ed.). (V. T. DeVita, T. S. Lawrence, S. A. Rosenberg, Eds.) Philadelphia: Lippincott William Wilkins.

Dine, J. L., O'Sullivan, C. C., Voeller, D., Greer, Y. E., Chavez, K. J., Conway, C. M., *et al.* (2016). The TRAIL Receptor Agonist Drozitumab Targets Basal B Triple Negative Breast Cancer Cells that Express Vimentin and Axl. *Breast Cancer Res Treat*, 155(2): 235-51. DOI: 10.1007/s10549-015-3673-z.

EBCTCG (Early Breast Cancer Trialists' Collaborative Group; McGale, P; Taylor, C; Correa, C; Cutter, D; *et al.* (2014, June). Effect of radiotherapy after

mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality. *Lancet*, 383(9935): 2127-35. DOI: 10.1016/S0140-6736(14)60488-8.

Echavarria, I., López-Tarruella, S., Picornell, A., García-Saenz, J. A., Jerez, Y., Hoadley, K., *et al.* (2018). Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. *Clin Cancer Res*, 24(8): 1845-52. DOI: 10.1158/1078-0432.CCR-17-1912.

Felipe Lima, J., Nofech-Mozes, S., Bayani, J., Bartlett, J. M. (2016). EMT in breast carcinoma—A review. *J. Clin. Med*, 5: 65. DOI: 10.3390/jcm5070065.

Foulkes, W. D., Smith, I. E., Reis-Filho, J. S. (2010, Nov). Triple-negative breast cancer. *N Engl J Med*, 363(20): 1938-48. DOI: 10.1056/NEJMra1001389.

Gerratana, L., Basile, D., Buono, G., De Placido, S., Giuliano, M., Minichillo, S., *et al.* (2018, Jul). Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. *Cancer Treat Rev*, 68: 102-10. DOI: 10.1016/j.ctrv.2018.06.005.

Ghozali, A. (2015). *Registrasi tumor berbasis data laboratorium patologi*. RSUP Dr. Sardjito, Instalasi Patologi Anatomi, Yogyakarta.

Gooding, A. J., Schiemann, W. P. (2020). Epithelial–Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance. *Mol Cancer Res*, 18(9): 1257-70. DOI: 10.1158/1541-7786.MCR-20-0067.

Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., *et al.* (2022). Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*, 20(6): 691-722. DOI: 10.6004/jnccn.2022.0030.

- Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., *et al.* (2013, Oct). Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer. *Clin Cancer Res*, 19(19): 5505–12. DOI: 10.1158/1078-0432.CCR-12-3327.
- Gucalp, A., Traina, T. A. (2016). Targeting the androgen receptor in triple-negative breast cancer. *Curr Probl Cancer*, 40: 141–50. DOI: 10.1016/j.crrprobcancer.2016.09.004.
- Hamm, C., Kulkarni, S., Gupta, R., Kay, A., Mathews, J., Hirmiz, K., *et al.* (2016). Early Stage Triple Negative Breast Cancer Has Significantly Better Outcomes than More Advanced Disease: A Single Centre Retrospective Review. *Journal of Cancer Therapy*, 7: 665-74. DOI: 10.4236/jct.2016.710069.
- Hammond, M. E., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., *et al.* (2010). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). *Arch Pathol Lab Med*, 134(7): e48. DOI: 10.5858/134.7.e48.
- Harborg, S., Zachariae, R., Olsen, J., Johannsen, M., Cronin-Fenton, D., Bøggild, H., Borgquist, S. (2021). Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis. *NPJ Breast Cancer*, 7(1): 119. DOI: 10.1038/s41523-021-00325-6.
- Hercules, S. M., Alnajar, M., Chen, C., Mladjenovic, S. M., Shipeolu, B. A., Perkovic, O., *et al.* (2022). Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis. *BMJ Open*, 12(5): e055735. DOI: 10.1136/bmjopen-2021-055735.
- Hernandez-Aya, L. F., Chavez-Macgregor, M., Lei, X., Meric-Bernstam, F., Buchholz, T. A., Hsu, L., *et al.* (2011). Nodal status and clinical outcomes in a large cohort

- of patients with triple-negative breast cancer. *J Clin Oncol*, 29(19): 2628-34. DOI: 10.1200/JCO.2010.32.1877.
- Hill, D. P., Harper, A., Malcolm, J., McAndrews, M. S., Mockus, S. M., Patterson, S. E., *et al.* (2019). Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance. *BMC Cancer*, 19(1): 1039. DOI: 10.1186/s12885-019-6278-9.
- Hubalek, M., Czech, T., Müller, H. (2017). Biological Subtypes of Triple-Negative Breast Cancer. *Breast Care (Basel)*, 12(1): 8-14. DOI: 10.1159/000455820.
- Huszno, J., Kolosza, Z. (2019). Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in breast cancer patients. *Oncol Lett*, 18(6): 6275-83. DOI: 10.3892/ol.2019.10966.
- Hutajulu, S. H., Prabandari, Y. S., Bintoro, B. S., Wiranata, J. A., Widiastuti, M., Suryani, N. D., *et al.* (2022). Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study. *PLoS One*, 17(1): e0262468. DOI: 10.1371/journal.pone.0262468.
- Jang, M. H., Kim, H. J., Kim, E. J., Chung, Y. R., Park, S. Y. (2015). Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. *Hum Pathol*, 46(9): 1267-74. DOI: 10.1016/j.humpath.2015.05.010.
- Jiralerspong, S., Goodwin, P. J. (2016). Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities. *J Clin Oncol*, 34(35): 4203-16. DOI: 10.1200/JCO.2016.68.4480.
- Kalluri, R., Neilson, E. G. (2003). Epithelial-mesenchymal transition and its implications for fibrosis. *J. Clin. Invest*, 112: 1776–84. DOI: 10.1172/JCI20530.

- Kaplan, H. G., Malmgren, J. A. (2008). Impact of triple negative phenotype on breast cancer prognosis. *Breast J*, 14: 456–63. DOI: 10.1111/j.1524-4741.2008.00622.x.
- Kassam, F., Enright, K., Dent, R., Dranitsaris, G., Myers, J., Flynn, C., *et al.* (2009). Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. *Clin Breast Cancer*, 9(1): 29-33. DOI: 10.3816/CBC.2009.n.005.
- Khillare, C. D., Khandeparkar, S. G., Joshi, A. R., Kulkarni, M. M., Gogate, B. P., Battin, S. (2019). Immunohistochemical Expression of Vimentin in Invasive Breast Carcinoma and Its Correlation with Clinicopathological Parameters. *Niger Med J*, 60(1): 17–21. DOI: 10.4103/nmj.NMJ_7_19.
- Kokkat, T. J., Patel, M. S., McGarvey, D., LiVolsi, V. A., Baloch, Z. W. (2013). Archived formalin-fixed paraffin-embedded (FFPE) blocks: A valuable underexploited resource for extraction of DNA, RNA, and protein. *Biopreserv Biobank*, 11(2): 101-6. DOI: 10.1089/bio.2012.0052.
- Kusinska, R. U., Kordek, R., Pluciennik, E., Bednarek, A. K., Piekarski, J. H., Potemski, P. (2009). Does vimentin help to delineate the so-called 'basal type breast cancer'? *J Exp Clin Cancer Res*, 28(1): 118. DOI: 10.1186/1756-9966-28-118.
- Lara-Medina, F., Pérez-Sánchez, V., Saavedra-Pérez, D., Blake-Cerda, M., Arce, C., Motola-Kuba, D., *et al.* (2011). Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. *Cancer*, 117: 3658-69. DOI: 10.1002/cncr.25961.
- Lee, A. J., Kim, K. I., Bae, J. W., Jung, Y. H., An, H., Lee, E. S., Korean Breast Cancer Society. (2010). Korean Breast Cancer Society. Triple negative breast cancer

in Korea—distinct biology with different impact of prognostic factors on survival. *Breast Cancer Res Treat*, 123: 177–87. DOI: 10.1007/s10549-010-0998-5.

Lehmann, B. D., Pietenpol, J. A. (2014). Identification and use of biomarkers in treatment strategies for triple negative breast cancer subtypes. *J Pathol*, 232(2): 142–50. DOI: 10.1002/path.4280.

Lehmann, B. D., Pietenpol, J. A. (2015). Triple-negative breast cancer: molecular subtypes and new targets for therapy. *Am Soc Clin Oncol Educ Book*, e: 31-9. DOI: 10.14694/EdBook_AM.2015.35.e31.

Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest*, 121(7): 2750–67. DOI: 10.1172/JCI45014.

Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., *et al.* (2016). Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. *PLoS ONE*, 11(6): e0157368. DOI: 10.1371/journal.pone.0157368.

Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., *et al.* (2008, Mar). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol*, 26(8): 1275-81. DOI: 10.1200/JCO.2007.14.4147.

Liedtke, C., Hess, K. R., Karn, T., Rody, A., Kiesel, L., Hortobagyi, G. N., *et al.* (2013). The prognostic impact of age in patients with triple-negative breast cancer. *Breast Cancer Res Treat*, 138(2): 591-9. DOI: 10.1007/s10549-013-2461-x.

- Lin, Y., Yin, W., Yan, T., Zhou, L., Di, G., Wu, J., *et al.* (2009). Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. *BMC Cancer*, 9: 342. DOI: 10.1186/1471-2407-9-342.
- Lin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., Winer, E. P. (2008). Sites of Distant Relapse and Clinical Outcomes in Patients with Metastatic Triple-Negative Breast Cancer: High Incidence of Central Nervous System Metastases. *Cancer*, 113(10): 2638–45. DOI: 10.1002/cncr.23930.
- Lin, N. U., Vanderplas, A., Hughes, M. E., Theriault, R. L., Edge, S. B., Wong, Y. N., *et al.* (2012). Clinicopathological Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network. *Cancer*, 118(22): 5463-72. DOI: 10.1002/cncr.27581.
- Lin, W. X., Xie, Y. N., Chen, Y. K., Cai, J. H., Zou, J., Zheng, J. H., *et al.* (2022). Nomogram for predicting overall survival in Chinese triple-negative breast cancer patients after surgery. *World J Clin Cases*, 10(31): 11338-48. DOI: 10.12998/wjcc.v10.i31.11338.
- Liu, S., Clouthier, S. G., Wicha, M. S. (2012). Role of microRNAs in the regulation of breast cancer stem cells. *J Mammary Gland Biol Neoplasia*, 17(1): 15-21.
- Lofterød, T., Mortensen, E. S., Nalwoga, H., Wilsgaard, T., Frydenberg, H., Risberg, T., *et al.* (2018). Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer *subtypes*. *BMC Cancer*, 18(1): 654. DOI: 10.1186/s12885-018-4568-2.
- Lund, M. J., Butler, E. N., Hairy, B. Y., Ward, K. C., Andrews, J. H., Oprea-Ilie, G., *et al.* (2010). Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. *Cancer*, 116: 2549-59. DOI: 10.1002/cncr.25016.

- Luo, X., Shi, Y. X., Li, Z. M., Jiang, W. Q. (2010). Expression and clinical significance of androgen receptor in triple negative breast cancer. *Chin J Cancer*, 29: 585–90. DOI: 10.5732/cjc.009.10673.
- Ma, F. J., Liu, Z. B., Qu, L., Hao, S., Liu, G. Y., Wu, J., Shao, Z. M. (2014). Impact of type 2 diabetes mellitus on the prognosis of early stage triple-negative breast cancer in People's Republic of China. *Onco Targets Ther*, 7: 2147-54. DOI: 10.2147/OTT.S71095.
- Ma, K. K., Chau, W. W., Wong, C. H., Wong, K., Fung, N., Lee, A. J., *et al.* (2012). Triple negative status is a poor prognostic indicator in Chinese women with breast cancer: a ten year review. *Asian Pac J Cancer Prev*, 13(5): 2109-14. DOI: 10.7314/apjcp.2012.13.5.2109.
- Madiyono, B., Moeslichan Mz, S., Sudigdo, S., Budiman, I., Purwanto, S. H. (2014). Perkiraan Besar Sampel. In B. Madiyono, S. Moeslichan Mz, S. Sudigdo, I. Budiman, S. H. Purwanto, S. Ismael, *et al.*, S. Sastroasmoro, S. Ismael (Eds.), *Dasar - dasar Metodologi Penelitian Klinis* (pp. 352-87). Jakarta: Sagung Seto.
- Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., *et al.* (2013). Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. *Clin Cancer Res*, 19(19): 5533-40. DOI: 10.1158/1078-0432.CCR-13-0799.
- Medina, M. A., Oza, G., Sharma, A., Arriaga, L. G., Hernández, J. M., Rotello, V. M., Ramirez, J. T. (2020). Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. *Int J Environ Res Public Health*, 17(6): 2078. DOI: 10.3390/ijerph17062078.
- Mittendorf, E. A., Kantor, O., Weiss, A., Richardson, E., Garrido-Castro, A., Portnow, L. H., *et al.* (2022). Nodal Positivity in Early-Stage Triple-Negative Breast

Cancer: Implications for Preoperative Immunotherapy. *Ann Surg Oncol*, 30(1): 100-6. DOI: 10.1245/s10434-022-12357-8.

Mohammed, M. E., Elhassan, N. M. (2019, Nov). Cytoskeletal and extracellular matrix proteins as markers for metastatic triple negative breast cancer. *J Int Med Res*, 47(11): 5767–76. DOI: 10.1177/0300060519877079.

Morris, G. J., Naidu, S., Topham, A. K., Guiles, F., Xu, Y., McCue, P., *et al.* (2007). Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients. *Cancer*, 110: 876–84. DOI: 10.1002/cncr.22836.

Morrow, M. (2000). The evaluation of common breast problem. *Am Fam Physician*, 61(8): 2371. <https://www.aafp.org/pubs/afp/issues/2000/0415/p2371.html>.

Mousavi, S. A., Kasaeian, A., Pourkasmaee, M., Ghavamzadeh, A., Alimoghaddam, K., Vaezi, M., *et al.* (2019). Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran. *PLoS One*, 14(1): e0208701. DOI: 10.1371/journal.pone.0208701.

Nanda, R., Liu, M. C., Yau, C., Asare, S., Hylton, N., Van't Veer, L., *et al.* (2017, May). Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. *J Clin Oncol*, 35(Suppl 15): abstract 506. DOI: 10.1001/jamaoncol.2019.6650.

Niemeier, L. A., Dabbs, D. J., Beriwal, S., Striebel, J. M., Bhargava, R. (2010). Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. *Mod Pathol*, 23: 205–12. DOI: 10.1038/modpathol.2009.159.

Nishimura, R., Arima, N. (2008). Is triple negative a prognostic factor in breast cancer? *Breast Cancer*, 15: 303–8. DOI: 10.1007/s12282-008-0042-3.

- Orlandini, L. F., Dos Reis, F. J., da Silveira, W. A., Tiezzi, M. G., de Andrade, J. M., Ribeiro-Silva, A., *et al.* (2018). Identification of a Subtype of Poorly Differentiated Invasive Ductal Carcinoma of the Breast Based on Vimentin and E-cadherin Expression. *Rev Bras Ginecol Obstet*, 40(12): 779-86. DOI: 10.1055/s-0038-1673700.
- O'Shaughnessy, J., Schwartzberg, L., Danso, M. A., Miller, K. D., Rugo, H. S., Neubauer, M., *et al.* (2014, Dec). Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer. *J Clin Oncol*, 32(34): 3840-7. DOI: 10.1200/JCO.2014.55.2984.
- Ostapenko, V., Želvienė, T. P., Smailytė, G., Ostapenko, A., Meškauskas, R. (2013). Triple negative breast cancer: 5-year results of combined treatment. *Acta Medica Lituanica*, 20(4). DOI: 10.6001/actamedica.v20i4.2816.
- Ovcaricek, T., Frkovic, S. G., Matos, E., Mozina, B., Borstnar, S. (2011). Triple negative breast cancer – prognostic factors and survival. *Radiol Oncol*, 45(1): 46-52. DOI: 10.2478/v10019-010-0054-4.
- Pareja, F., Reis-Filho, J. S. (2018). Triple-negative breast cancers - a panoply of cancer types. *Nat Rev Clin Oncol*, 15(6): 347-8. DOI: 10.1038/s41571-018-0001-7.
- Petrelli, F., Coinu, A., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V., Barni, S. (2014). The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. *Breast Cancer Res Treat*, 144(2): 223-32. DOI: 10.1007/s10549-014-2876-z.
- Plasilova, M. L., Hayse, B., Killelea, B. K., Horowitz, N. R., Chagpar, A. B., Lannin, D. R. (2016). Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database. *Medicine (Baltimore)*, 95(35): e4614. DOI: 10.1097/MD.00000000000004614.

Poggio, F., Lambertini, M., Bighin, C., Conte, B., Blondeaux, E., D'Alonzo, A., et al. (2018). Management of young women with early breast cancer. *ESMO Open*, 3(Suppl 1): e000458. DOI: 10.1136/esmoopen-2018-000458.

Pogoda, K., Niwinska, A., Murawska, M., Pienkowski, T. (2013). Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. *Med Oncol*, 30: 388. DOI: 10.1007/s12032-012-0388-4.

Prat, A., Perou, C. M. (2009). Mammary development meets cancer genomics. *Nat Med*, 15(8): 842-4. DOI: 10.1038/nm0809-842.

Prat, A., Adamo, B., Cheang, M. C., Anders, C. K., Carey, L. A., Perou, C. M. (2013). Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer. *The Oncologist*, 18: 123–33. DOI: 10.1007/s10549-014-3056-x.

Prat, A., Cheang, M. C., Galvan, P., Nuciforo, P., Pare, L., Adamo, B., et al. (2016). Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. *JAMA Oncol*, 2(10): 1287-94. DOI: 10.1001/jamaoncol.2016.0922.

Purwanto, I., Heriyanto, D. S., Ghozali, A., Widodo, I., Dwiprahasto, I., Aryandono, T., Haryana, S. M. (2020). Basal-Like Subgroup is Associated with Younger Age, Increased Expression of Androgen Receptor, and Worse Prognosis, while Non-basal-like Subtype is Associated with Higher BMI in Triple-Negative Breast Cancer Patients. *Indones Biomed J*, 12(4): 349-54. DOI: 10.18585/inabj.v12i4.1289.

Purwanto, I., Heriyanto, D. S., Ghozali, A., Widodo, I., Dwiprahasto, I., Aryandono, T., Haryana, S. M. (2020). Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple

Negative Breast Cancer. *World J Oncol*, 11(5): 216-22. DOI: 10.14740/wjon1302.

Purwanto, I., Heriyanto, D. S., Widodo, I., Hakimi, M., Hardianti, M. S., Aryandono, T., Haryana, S. M. (2021). MicroRNA-223 is Associated with Resistance Towards Platinum-based Chemotherapy and Worse Prognosis in Indonesian Triple-negative Breast Cancer Patients. *Breast Cancer (Dove Med Press)*, 13: 1-7. DOI: 10.2147/BCTT.S291014.

Rangel, N., Villegas, V. E., Rondón-Lagos, M. (2021). Obesity and Androgen Receptor Signaling: Associations and Potential Crosstalk in Breast Cancer Cells. *Cancers (Basel)*, 13(9): 2218. DOI: 10.3390/cancers13092218.

Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., *et al.* (2017, Aug). Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. *N Engl J Med*, 377(6): 523-33. DOI: 10.1056/NEJMoa1706450.

Rugo, H. S., Olopade, O. I., DeMichele, A., Yau, C., van 't Veer, L.J., Buxton, M. B., *et al.* (2016, Jul). Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer. *N Engl J Med*, 375(1): 23–34. DOI: 10.1056/NEJMoa1513749.

Rygiel, K. (2021). Interface between obesity with dysfunctional metabolism and inflammation, and the triple-negative breast cancer in African American women. *Explor Target Antitumor Ther*, 2(6): 602-16. DOI: 10.37349/etat.2021.00066.

Schmid, P., Park, Y. H., Muñoz-Couselo, E., Kim, S. B., Sohn, J., Im, S. A., *et al.* (2017, May). Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. *J Clin Oncol*, 35(suppl): abstract 556. DOI: 10.1016/j.annonc.2020.01.072.

- Schmidt, G., Solomayer, E. F., Bohle, R. M., Gerlinger, C., Radosa, J. C., Endrikat, J., Kasoha, M. (2020). Is vimentin a potential prognostic factor for patients with triple-negative breast cancer? *J Cancer Res Clin Oncol*, 146(8): 2109-16. DOI: 10.1007/s00432-020-03210-0.
- Schoenfeld, D. A. (1983). Sample-size formula for the proportional-hazards regression model. *Biometrics*, 39: 499-503. <https://pubmed.ncbi.nlm.nih.gov/6354290>.
- Siddharth, S., Sharma, D. (2018). Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. *Cancers (Basel)*, 10(12): 514. DOI: 10.3390/cancers10120514.
- Sikov, W. M., Dizon, D. S., Strenger, R., Legare, R. D., Theall, K. P., Graves, T. A., *et al.* (2009). Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. *J Clin Oncol*, 27:4693–700. DOI: 10.1200/JCO.2008.21.4163.
- Stead, L. A., Lash, T. L., Sobieraj, J. E., Chi, D. D., Westrup, J. L., Charlot, M., *et al.* (2009). Triple-negative breast cancers are increased in black women regardless of age or body mass index. *Breast Cancer Res*, 11: R18. DOI: 10.1186/bcr2242.
- Su, Y., Hopfinger, N. R., Nguyen, T. D., Pogash, T. J., Santucci-Pereira, J., Russo, J. (2018). Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors. *J Exp Clin Cancer Res*, 37(1): 314. DOI: 10.1186/s13046-018-0988-8.
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F. (2021, May). Global Cancer Statistics 2020: GLOBOCAN Estimates of

- Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*, 71(3): 209-49. DOI: 10.3322/caac.21660.
- Tait, S., Pacheco, J. M., Gao, F., Bumb, C., Ellis, M. J., Ma, C. X. (2014). Body mass index, diabetes, and triple-negative breast cancer prognosis. *Breast Cancer Res Treat*, 146(1): 189-97. DOI: 10.1007/s10549-014-3002-y.
- Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O'Shaughnessy, J., *et al.* (2018, Jan). Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. *J Clin Oncol*, JCO2016713495. DOI: 10.1200/JCO.2016.71.3495.
- Trivers, K. F., Lund, M. J., Porter, P. L., Liff, J. M., Flagg, E. W., Coates, R. J., Eley, J. W. (2009, September). The epidemiology of triple-negative breast cancer, including race. *Cancer Causes Control*, 20(7): 1071-82. DOI: 10.1007/s10552-009-9331-1.
- Tseng, L. M., Hsu, N. C., Chen, S. C., Lu, Y. S., Lin, C. H., Chang, D. Y., *et al.* (2013). Distant metastasis in triple-negative breast cancer. *Neoplasma*, 60(3): 290-4. DOI: 10.4149/neo_2013_038.
- Tumonggor, M. K., Karafet, T. M., Hallmark, B., Lansing, J. S., Sudoyo, H., Hammer, M. F., Cox, M. P. (2013). The Indonesian archipelago: an ancient genetic highway linking Asia and the Pacific. *J Hum Genet*, 58(3): 165-73. DOI: 10.1038/jhg.2012.154.
- Tzikas, A. K., Nemes, S., Linderholm, B. K. (2020). A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns. *Breast Cancer Res Treat*, 182(3): 643-54. DOI: 10.1007/s10549-020-05727-x.
- UK Chemotherapy Board. (2021). The Management of Glycaemic Control in People with Cancer. <https://www.uksactboard.org/publications>

- Vona-Davis, L., Rose, D. P., Hazard, H., Howard-McNatt, M., Adkins, F., Partin, J., Hobbs, G. (2008). Triple-negative breast cancer and obesity in a rural Appalachian population. *Cancer Epidemiol Biomarkers Prev*, 17(12): 3319-24. DOI: 10.1158/1055-9965.EPI-08-0544.
- Wahidin, M., Noviani, R., Hermawan, S., Andriani, V., Ardian, A., Djarir, H. (2012). Population-Based Cancer Registration in Indonesia. *Asian Pacific J Cancer Prev*, 13: 1709-10. DOI: 10.7314/apjcp.2012.13.4.1709.
- Wahidin, M., Febrianti, R., Susanty, F., Hasanah, S. R. (2022). Twelve Years Implementation of Cervical and Breast Cancer Screening Program in Indonesia. *Asian Pac J Cancer Prev*, 23(3): 829-37. DOI: 10.31557/APJCP.2022.23.3.829.
- Winter, M., Meignan, S., Völkel, P., Angrand, P. O., Chopin, V., Bidan, N., *et al.* (2021). Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment. *Cells*, 10(6): 1504. DOI: 10.3390/cells10061504.
- Wolff, A. C., Hammond, M. E., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., *et al.* (2013). Recommendation for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologist clinical practice guideline update. *J Clin Oncol*, 31(31): 3997. DOI: 10.1200/JCO.2013.50.9984.
- Yamashita, N., Tokunaga, E., Kitao, H., Hisamatsu, Y., Taketani, K., Akiyoshi, S., *et al.* (2013, May). Vimentin as a poor prognostic factor for triple-negative breast cancer. *J Cancer Res Clin Oncol*, 139(5): 739-46. DOI: 10.1007/s00432-013-1376-6.

- Yao, Y., Chu, Y., Xu, B., Hu, Q., Song, Q. (2019). Risk factors for distant metastasis of patients with primary triple-negative breast cancer. *Biosci Rep*, 39(6): BSR20190288. DOI: 10.1042/BSR20190288.
- Yaourtis, A. M., Levina, A., Lay, P. A. (2022). Tumour cell heterogeneity in triple-negative breast cancer cells affects response to cisplatin, but not doxorubicin. *J Inorg Biochem*, 239: 112082. DOI: 10.1016/j.jinorgbio.2022.112082.
- Yuan, N., Meng, M., Liu, C., Feng, L., Hou, L., Ning, Q., *et al.* (2014). Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. *Mol Clin Oncol*, 2(2): 245-51. DOI: 10.3892/mco.2013.230.
- Zhu, W., Perez, E. A., Hong, R., Li, Q., Xu, B. (2015). Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries. *PLoS One*, 10(5): e0128345. DOI: 10.1371/journal.pone.0128345.